文献速递消化系统肿瘤支持与姑息治疗

11种癌症的高突变肿瘤可分为三种免疫亚型

Hypermutated tumours across 11 cancer types show three distinct immune subtypes.
PubMed 文献 · Eur J Cancer · 2021-03-19

该研究对TCGA中11种癌症的5519个肿瘤及亚洲队列338例结直肠癌样本的体细胞突变数据进行分析,将肿瘤突变负荷>10 mut/Mb定义为高突变(HM),对1040例有转录组数据的HM样本进行非负矩阵分解聚类,发现HM肿瘤可分为HM1、HM2和HM3三种免疫亚型,其中HM3型CD8 T细胞浸润增加、TCR多样性高、免疫评分高且生存期延长,HM2型则与丰富基质成分、上皮间质转化、TGFβ、血管生成特征及不良预后相关。

要点

  • 高突变肿瘤可分为HM1、HM2、HM3三种免疫亚型。
  • HM3型CD8 T细胞浸润增加、TCR多样性高、免疫评分高且生存期延长。
  • HM2型与丰富基质成分、上皮间质转化、TGFβ、血管生成特征及不良预后相关。

核心结论

  • 高突变肿瘤并非均一,可分为三种具有不同免疫特征和预后的亚型。
  • HM3型免疫浸润活跃且预后较好,HM2型基质丰富且预后较差。

研究设计与样本

  • 对TCGA中11种癌症的5519个肿瘤及亚洲队列338例结直肠癌样本的体细胞突变数据进行统计分析。
  • 将肿瘤突变负荷>10 mut/Mb的样本定义为高突变(HM)。
  • 对1040例具有转录组数据的HM样本进行非负矩阵分解聚类。

主要发现

  • HM肿瘤可分为HM1、HM2和HM3三种免疫亚型。
  • HM3型与CD8 T细胞浸润增加、TCR多样性高、免疫评分高及生存期延长相关。
  • HM2型与丰富基质成分、上皮间质转化、TGFβ、血管生成特征及不良预后相关。
  • 在结直肠癌中通过免疫荧光验证了HM3型CD8 T细胞浸润更多及趋化因子表达增加。

临床怎么用

  • 这些发现有助于未来开发针对亚型的治疗策略以提高疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Complete remission is observed in less than half of hypermutated (HM) tumours after immune checkpoint blockade therapy, indicating that HM tumours are very heterogeneous. Thus, there is an urgent requirement to decipher the unknown intrinsic HM tumour subtypes. METHODS: Statistical analysis was performed on somatic mutation data from 5519 tumours across 11 cancer types obtained from The Cancer Genome Atlas and 338 colorectal cancer (CRC) samples obtained from an Asian cohort. Samples with a tumour mutation burden >10 mut/Mb were classified as HM. A total of 1040 HM samples harbouring corresponding transcriptomes were used for non-negative matrix factorisation clustering. Tumour mutational burden, neoantigens, T cell receptor (TCR) diversity, stromal score and immune score were compared between the subtypes. RESULTS: HM tumours fell into three distinct immune subtypes: HM1, HM2 and HM3. HM3 tumours were correlated with increased CD8 T cell infiltration, high TCR diversity, a high immune score and prolonged survival. HM2 tumours were correlated with an abundant stromal component, epithelial-mesenchymal transition, TGFβ, angiogenesis hallmarks and poor outcomes. The infiltration of more CD8 T cells and increased chemokine expression in HM3 were validated in CRC by immunofluorescence. CONCLUSIONS: These findings will facilitate the development of a subtype-oriented therapy strategy to enhance the treatment effect in the near future.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hu W, Chen J, Qi L, et al. Hypermutated tumours across 11 cancer types show three distinct immune subtypes. Eur J Cancer. 2021. PMID: 33752133. doi:10.1016/j.ejca.2021.01.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。